Abstract 470P
Background
Due to its high propensity for metastasis and lack of durable response to therapy, several biomarkers have been studied to help predict outcomes in patients with Small Cell Lung Cancer (SCLC). These biomarkers aid the clinicians in their treatment decisions among these patients. Neuron-specific enolase (NSE), can be used in supporting a diagnosis of SCLC. However, little is known on its prognostic significance due to the limited number of studies conducted. Carcino-embryonic antigen (CEA) can be used in treatment monitoring and prognostication in several cancers. Few studies have been conducted among SCLC patients investigating its prognostic significance. Moreover, no meta-analysis has been conducted on this outcome. Vascular endothelial growth factor (VEGF) plays an important role in the dissemination of malignancy. Although serum VEGF is found many cancer patients, little is known about its prognostic significance among SCLC. Moreover, no meta-analysis has been conducted on this outcome. This study aims to conduct a systematic review and meta-analysis on the prognostic significance of the CEA, NSE and VEGF on SCLC.
Methods
A systematic review was conducted to examine the prognostic significance of three biomarkers in the prognosis of SCLC: CEA, VEGF and NSE. Systematic search was done using Pubmed, Cochraine and EMBASE for articles published until July 1, 2019. Seventeen studies with a total of 3, 973 patients were included in the analysis. The primary outcome of interest was Overall Survival in SCLC. Data was summarized using RevMan 5.3. Preplanned subgroup analysis was done on the type of study and the statistic used.
Results
High CEA (HR 1.28 95%CI 1.10-1.50, p < 0.001, I2 45%) and VEGF (HR 1.84 CI 1.21-2.78 p = 0.004, I2 52%) were both associated with poor overall survival. NSE was associated with poor overall survival based on pooled retrospective studies (HR 1.42 CI 1.22-1.67, p < 0.00001, I2 34%) and prospective studies (RR 1.68 CI 1.40-2.02, p < 0.00001, I2 50%). Pooled HR for prospective studies was not significant (HR 2.32 CI 0.96-5.56, p = 0.06, I2 83%).
Conclusions
High NSE, CEA and VEGF may be used as prognostic biomarkers of poor survival in patients with SCLC. Further randomized studies may confirm these findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D.B.L. Sacdalan: Honoraria (self): Merck. All other authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract